People: Clinical Data Inc (CLDA.O)

CLDA.O on Consolidated Issue listed on NASDAQ Global Market

15.90USD
11:25am EST
Price Change (% chg)

$0.53 (+3.45%)
Prev Close
$15.37
Open
$15.29
Day's High
$15.90
Day's Low
$15.29
Volume
33,908
Avg. Vol
75,816
52-wk High
$21.94
52-wk Low
$7.36

view people for:

Summary

Name Age Since Current Position
Kirk, Randal 55 2004 Chairman of the Board
Fromkin, Andrew 43 2006 President, Chief Executive Officer, Director
Ballantyne, C. Evan 50 2009 Chief Financial Officer, Executive Vice President
Belbel, Caesar 49 2005 Executive Vice President, Chief Legal Officer and Secretary
Reed, Carol 56 2008 Executive Vice President, Chief Medical Officer
Malman, Arthur 67 1975 Director
Horner, Larry 75 2002 Director
Sobel, Burton 71 2005 Director
Wallace, Richard 58 2008 Director
Tarriff, Scott 46 2009 Director
» Insider Trading

Biographies

Name Description
Kirk, Randal Randal J. Kirk is Chairman of the Board of Clinical Data, Inc. He is the Senior Managing Director and Chief Executive Officer of Third Security, LLC, an investment management firm founded by Mr. Kirk. Additionally, Mr. Kirk founded and became Chairman of the Board of New River Pharmaceuticals Inc. (previously traded on Nasdaq prior to its acquisition by Shire plc in 2007) in 1996, and was President and Chief Executive Officer between October 2001 and April 2007. Mr. Kirk began his professional career in the private practice of law. Previously, Mr. Kirk served as a member of the Board of Directors of Scios, Inc. (previously traded on Nasdaq prior to its acquisition by Johnson & Johnson) between February 2000 and May 2002. Mr. Kirk currently serves in a number of additional capacities including as a member of the Board of Directors of Clinical Data, Inc. since 2002 and Chairman of the Board since 2004; member of the Board of Directors of Halozyme Therapeutics, Inc. (Nasdaq: HALO) since May 2007; as Chairman of the Board of Directors of Intrexon Corporation since February 2008 and Chief Executive Officer since April 2009; and as Chairman of the Board of Directors of Cyntellect, Inc. since September 2008. Mr. Kirk received a B.A. in Business from Radford University and a J.D. from the University of Virginia.
Fromkin, Andrew Andrew J. Fromkin joined Clinical Data on October 12, 2005 and was elected President and Chief Executive Officer of Clinical Data, Inc. on May 12, 2006. Mr. Fromkin has twenty years of senior leadership experience in a variety of roles and in various areas of the healthcare industry with an emphasis on care delivery, information, and pharmaceutical services. Prior to Clinical Data, Mr. Fromkin held several senior management roles at emerging healthcare companies and worked as a consultant to develop and launch a major personal health program strategy and system with a major national healthcare insurer. Most recently he was President and Chief Executive Officer of DoctorQuality, Inc., a major provider of patient safety and condition management products that was acquired by Quantros, Inc. Previously, Mr. Fromkin served as President and Chief Executive Officer of Endo Surgical Devices, Inc., an early stage surgical instrument developer. Mr. Fromkin spent most of the 1990’s in two leadership roles with Medco, then Merck-Medco Managed Care, LLC, a wholly owned subsidiary of Merck & Co., Inc. They included Vice President, Business Development and before that, Vice President, Sales. Mr. Fromkin began his career at Health Information Technologies, a leader in the then emerging field of electronic data interchange.
Ballantyne, C. Evan C. Evan Ballantyne joined Clinical Data as Senior Vice President and Chief Financial Officer on August 7, 2006. In 2009, Mr. Ballantyne was elected Executive Vice President and Chief Financial Officer of Clinical Data. He was most recently Senior Vice President and Chief Financial Officer of ZymeQuest, Inc., a medical technology company based in Beverly, Massachusetts, and previously was the Chief Financial Officer of Knowledge Impact, of Wayland, Massachusetts. Earlier, Mr. Ballantyne was a Vice President and Chief Operating Officer for ACNielsen Corporation and held the Chief Financial Officer position as well for two years. Mr. Ballantyne also held an audit position for Dun & Bradstreet, earned a B.A. from the University of Western Ontario, and earned a post-graduate degree in Business Administration with Honors from the University of Windsor.
Belbel, Caesar Caesar J. Belbel joined Clinical Data, Inc. as Vice President and General Counsel on May 7, 2003, and was elected Secretary of Clinical Data on June 25, 2003. Mr. Belbel was subsequently elected Senior Vice President in May 2005 and Executive Vice President of Clinical Data in October 2005. Prior to joining Clinical Data, Mr. Belbel served from 2000 to 2002 as Senior Vice President, General Counsel and Secretary of Xpedior Incorporated, a publicly-held Internet consulting services and e-commerce software development company. Previously, from 1997 to 2000, Mr. Belbel served as General Counsel of Programart Corporation, a developer of application performance management software. Mr. Belbel holds a Bachelor of Arts degree from Columbia University and a Juris Doctor degree from Boston College Law School.
Reed, Carol Carol R. Reed, M.D. joined Clinical Data, Inc. in October 2005 as Senior Vice President and Chief Medical Officer following the completion of its merger with Genaissance Pharmaceuticals, Inc., where Dr. Reed had served as Vice President, Medical Affairs since 2003. In April 2008, Dr. Reed was elected Executive Vice President and Chief Medical Officer of Clinical Data. Dr. Reed joined Genaissance from Bayer Pharmaceuticals, Inc., where she was an Associate Medical Director in Pulmonary Medical Research. Previously, she was the Associate Director, Section of Pulmonary and Critical Care Medicine, at the Hospital of St. Raphael and directed its Medical Intensive Care Unit. Dr. Reed received a M.S. in biology from the University of Illinois and a M.D. from Rush Medical College in Chicago.
Malman, Arthur Arthur B. Malman is a Director of Clinical Data, Inc. He is a partner of the law firm of Malman & Goldman, LLP and a principal of the Urban Group, a real-estate investment company. Mr. Malman is also Chairman of Dimex Holdings Corporation, a telecom venture company and a director of PS America, Inc. a floor covering chain. Mr. Malman received a B.A. from Princeton University and a J.D. from the Yale University School of Law, and attended Columbia University School of Business Administration.
Horner, Larry Larry D. Horner is a Director of Clinical Data, Inc. He served as a member of the Board of Directors of New River Pharmaceuticals Inc., and American General Corp until they were sold and ConocoPhillips until he reached the mandatory retirement age. From 1994 to 2001, Mr. Horner served as Chairman of the Board of Pacific USA Holdings Corporation, a holding company of companies in real estate and financial services. From 1997 to 2001, Mr. Horner served as Chairman of the Board of Asia Pacific Wire & Cable, Ltd., a publicly-traded manufacturer of wire and cable products for the telecommunications and power industries in the Asia Pacific Region. From 1991 to 1994, he served as Managing Director of Arnhold & S. Bleichroeder, Inc., an equity market trading and corporate finance firm. Prior to that, he served as Chairman and Chief Executive Officer of the accounting firm KPMG Peat Marwick. In 2009, Mr. Horner retired from the Board of Directors of UTStarcom, Inc. and Atlantis Plastics, Inc. Mr. Horner continues to serve on the Board of Directors of TOUSA, Inc. (OTC: TOUSQ) and Intrexon Corporation.
Sobel, Burton Burton E. Sobel, M.D. is a Director of Clinical Data, Inc. He has been at the University of Vermont since 1994 where he is currently Professor of Medicine, Director of the Cardiovascular Research Institute, and Professor of Biochemistry. Dr. Sobel has been a trustee of Fletcher Allen Health Care Center in Burlington, Vermont. Previously, he held senior academic and administrative positions at Washington University School of Medicine and Barnes Hospital from 1973 to 1994, and at the University of California, San Diego, from 1968 to 1973. Dr. Sobel completed postgraduate training at the Peter Bent Brigham Hospital, Boston and the National Institutes of Health, Bethesda and received his M.D., magna cum laude, from Harvard University and his A.B. from Cornell University. Dr. Sobel is President of the Society for Experimental Biology and Medicine and also serves as a member of the Board of Directors of Nuvelo, Inc. and Ariad Pharmaceuticals, Inc., both publicly-traded life science companies. Dr. Sobel also served as a member of the Board of Directors of New River Pharmaceuticals Inc., a publicly-traded specialty pharmaceutical company focused on developing novel pharmaceuticals and improved versions of widely-prescribed drugs, from 2004 until its acquisition by Shire plc in April 2007. Dr. Sobel serves on the Board of Directors of Intrexon Corporation.
Wallace, Richard Richard J. Wallace serves as Director of Clinical Data, Inc. He has fifteen years experience at GlaxoSmithKline (GSK) from 1992 until January 2008, spanning roles from Vice President Commercial (Canadian Pharmaceuticals), Vice President U.S. Business Development, Vice President Sales & Marketing ( U.S. Oncology and HIV), Vice President Clinical Development and Product Strategy, to Senior Vice President Global Commercial Strategy. He served as a member of GSK’s Research and Development Executive, Commercial Operations Committee and Product Management Board. His experience prior to joining GSK includes eight years with Bristol Myers Squibb and seven years at Johnson & Johnson in assignments from marketing, sales, manufacturing and general management. Mr. Wallace currently serves on the board of directors of Avigen Inc, ImmunoGen Inc and Bridgehead International Ltd. Mr. Wallace received B.Com. and B.Com.Honors degrees from Rhodes University, South Africa.
Tarriff, Scott Mr. Scott Tarriff is Director of Clinical Data, Inc. In January 2007, Mr. Tarriff formed Eagle Pharmaceuticals, Inc., a hospital specialty company focused on developing, distributing and in-licensing injectable IV products. Prior to forming Eagle, Mr. Tarriff was President and Chief Executive Officer of Par Pharmaceutical Companies, Inc. He joined Par Pharmaceutical Companies, Inc. as Executive Vice President of Business in 1998 and was named President and Chief Executive Officer of Par Pharmaceutical, Inc., the company's principal operating subsidiary, in 2001. Mr. Tarriff was elected to its Board of Directors in 2002 and appointed President and Chief Executive Officer of Par Pharmaceutical Companies, Inc. in September 2003. Pennsylvania. Mr. Tarriff joined Par following over a decade with Bristol-Meyers Squibb. He received his Master of Business Administration from Rider College and his undergraduate degree from Pennsylvania State University.

Basic Compensation

Name Fiscal Year Total
Kirk, Randal --
Fromkin, Andrew 2,457,250
Ballantyne, C. Evan 784,953
Belbel, Caesar 918,040
Reed, Carol 881,094
Malman, Arthur --
Horner, Larry --
Sobel, Burton --
Wallace, Richard --
Tarriff, Scott --
As Of 30 Mar 2009

Options Compensation

Name Options Value
Kirk, Randal 0 0
Fromkin, Andrew 53,333 135,280
Ballantyne, C. Evan 0 0
Belbel, Caesar 75,691 446,226
Reed, Carol 5,000 41,317
Malman, Arthur 0 0
Horner, Larry 0 0
Sobel, Burton 0 0
Wallace, Richard 0 0
Tarriff, Scott 0 0

Insider Trading

Name Shares Traded Price
MALMAN ARTHUR BARRY 400 $0.00
TARRIFF SCOTT L 9,000 $0.00
HORNER LARRY D 9,000 $0.00
FROMKIN ANDREW J 2,000 $9.56
KIRK RANDAL J 605,966 $16.50
KIRK RANDAL J 121,194 $16.50
KIRK RANDAL J 48,478 $16.50
KIRK RANDAL J 424,178 $16.50
KIRK RANDAL J 24,240 $16.50
KIRK RANDAL J 242,388 $16.50
KIRK RANDAL J 48,478 $16.50
MALMAN ARTHUR BARRY 9,166 $0.00
HORNER LARRY D 9,166 $0.00
KIRK RANDAL J 18,334 $0.00
MALMAN ARTHUR BARRY 4,480 $15.07
MALMAN ARTHUR BARRY 22,500 $3.33
FROMKIN ANDREW J 2,000 $15.00
KIRK RANDAL J 5,985 $16.49
» Full list on Insider Trading
view people for: